Date	Headline
Oct 15, 2020	Provectus Biopharmaceuticals Announces Acceptance of PV-10® Pancreatic Cancer Abstract at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 05, 2020	Provectus Biopharmaceuticals Completes Enrollment of PV-10® Study for Treatment of Symptomatic Neuroendocrine Tumors Metastatic to the Liver Refractory to Somatostatin Analogs and Peptide Receptor Radionuclide Therapy
Sep 21, 2020	Provectus Biopharmceuticals Highlights Stage IV M1d Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
Sep 21, 2020	Provectus Biopharmaceuticals Highlights Stage IV M1c Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
Sep 17, 2020	Provectus Biopharmaceuticals Announces Presentation of Preliminary Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

Our Contact Form	Mailing Address
Telephone: +1 (866) 594-5999 Fax: +1 (866) 998-0005 info@pvct.com	Provectus Biopharmaceuticals, Inc. 10025 Investment Drive, Suite 250 Knoxville, TN 37932
Investor Relations	Media Relations
Provectus Biopharmaceuticals, Inc. Email: investorrelations@pvct.com Phone: +1 (866) 594-5999 x1	Provectus Biopharmaceuticals, Inc. E-mail: mediarelations@pvct.com Phone: +1 (866) 594-5999 x4
Transfer Agent
(i.e. stockholder records, transfer, change of address, etc.) Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, NY 11717 E-mail: shareholder@broadridge.com Telephone: +1 (877) 830-4936 Fax: +1 (215) 553-5402

Filing Date	Form Type	Description	View
Aug 12, 2020	10-Q	Quarterly report	html pdf xbrl
May 13, 2020	10-Q	Quarterly report	html pdf xbrl
Mar 05, 2020	10-K	Annual report	html pdf xbrl
Nov 12, 2019	10-Q	Quarterly report	html pdf xbrl
Aug 08, 2019	10-Q	Quarterly report	html pdf xbrl

Company Overview